Activity & safety of spartalizumab (PDR001) in patients (pts) with advanced neuroendocrine tumors (NET) of pancreatic (Pan), gastrointestinal (GI), or thoracic (T) origin, & gastroenteropancreatic neuroendocrine carcinoma (GEP NEC) who have progressed on prior treatment (Tx)

Yao JC, Strosberg J, Fazio N, Pavel ME, Ruszniewski P, Bergsland E, Li D, Tafuto S, Raj N, Campana D, Hijioka S, Raderer M, Guimbaud R, Gajate P, Pusceddu S, Reising A, Degtyarev E, Mookerjee B, Aimone P, Singh S (2018)

Publication Type: Conference contribution

Publication year: 2018

Journal

Publisher: OXFORD UNIV PRESS

City/Town: OXFORD

Conference Proceedings Title: ANNALS OF ONCOLOGY

Event location: Munich

DOI: 10.1093/annonc/mdy293.001

Authors with CRIS profile

Involved external institutions

European Institute of Oncology / Istituto Europeo di Oncologia (IEO) Italy (IT) Beaujon Hospital / Hôpital Beaujon France (FR) Ospedaliero Universitaria di Bologna Policlinico S.Orsola-Malpighi Italy (IT) UCSF Helen Diller Family Comprehensive Cancer Center United States (USA) (US) University of Texas MD Anderson Cancer Center United States (USA) (US) Medizinische Universität Wien Austria (AT) H. Lee Moffitt Cancer Center & Research Institute United States (USA) (US) Aichi Cancer Center Research Institute Japan (JP) Istituto Nazionale Tumori IRCCS "Fondazione G. Pascale" Italy (IT) Memorial Sloan Kettering Cancer Center United States (USA) (US) Hospital Universitario Ramón y Cajal Spain (ES) Novartis AG Switzerland (CH) Sunnybrook Health Sciences Centre Canada (CA) City of Hope Medical Center United States (USA) (US) Centre Hospitalier Universitaire (CHU) de Toulouse France (FR) Fondazione IRCCS: Istituto Nazionale dei Tumori Italy (IT)

How to cite

APA:

Yao, J.C., Strosberg, J., Fazio, N., Pavel, M.E., Ruszniewski, P., Bergsland, E.,... Singh, S. (2018). Activity & safety of spartalizumab (PDR001) in patients (pts) with advanced neuroendocrine tumors (NET) of pancreatic (Pan), gastrointestinal (GI), or thoracic (T) origin, & gastroenteropancreatic neuroendocrine carcinoma (GEP NEC) who have progressed on prior treatment (Tx). In ANNALS OF ONCOLOGY. Munich, DE: OXFORD: OXFORD UNIV PRESS.

MLA:

Yao, J. C., et al. "Activity & safety of spartalizumab (PDR001) in patients (pts) with advanced neuroendocrine tumors (NET) of pancreatic (Pan), gastrointestinal (GI), or thoracic (T) origin, & gastroenteropancreatic neuroendocrine carcinoma (GEP NEC) who have progressed on prior treatment (Tx)." Proceedings of the 43rd ESMO Congress (ESMO), Munich OXFORD: OXFORD UNIV PRESS, 2018.

BibTeX: Download